Management Team
Alpha Bioventure’s founder team is made up of 2 renowned experts who have rich experience in developing and launching biopharmaceuticals and uncover novel therapeutics. Based on the thorough understanding of drug discovery and the international market, we could find valued life sciences development programs and incubate them to grow into an established company.
John J. Baldwin
Ph. D.
Founding Partner
Bo Liang
Ph. D. MBA
Founding Partner
- Has more than 50 years of experience in drug discovery and exploring new technologies.
- More than 30 years at Merck Research Laboratories, and invented several drugs to his credit including Trusopt®, Cosopt®, both for the treatment of glaucoma, cardiovascular medicine Aggrastat®, AIDS medicine Crixivan®, and peptic ulcer disease medicine Pepcid®.
- Founder and Chief Scientific Officer of Pharmacopeia, a company specializing in new drug discovery technologies and advancing drugs into clinical phase. Pharmacopeia was listed in NASDAQ in 1995 after founded in 1993.
- Founder, President and Chief Scientific Officer for Vitae Pharmaceuticals where he applies computational and molecular simulation methods to the discovery of new therapeutic agents. Vitae Pharmaceuticals was listed in NASDAQ and merged by Allergan for $650 million in 2016.
- Co-Founder and Board member of WuXi PharmaTech in Shanghai, China, Hua Medicine and IVIEW Therapeutics Inc.
- Published over 100 scientific articles and numerous reviews and has been an invited lecturer at more than 125 national and international symposiums.
- Holds over 180 issued United States patents.
- Received several awards including the prestigious Hershberg Award for Important Discoveries in Medically Active Substance and the Outstanding Achievement Award by the University of Minnesota and was inducted into “Hall of Fame” by American Chemical Society Medicinal Chemistry Section.
- Bachelor in Chemistry, the University of Delaware; Ph.D., the University of Minnesota.
- Founder & President of IVIEW Therapeutics Inc. since 2015. IVIEW focuses on developing ophthalmic, nasal and wound care medications. Its lead compound, Iview-1201 for the treatment of acute conjunctivitis (“pink eye”), is scheduled to begin human phase II trials in 2018.
- In 2010 Established Adesso Advanced Materials and successfully developed the world first Recycloset® recyclable thermoset resin technology and recyclable carbon fiber composites. The products are qualified as lightweight materials for New Energy Vehicles.
- Former Executive Vice President of Foresight Biotherapeutics, Inc. (New York) from 2008 to 2010. Led development of FST-100 and Foresight was acquired by Shire Plc. in 2015 for $300 million after FST-100 completing phase II clinical trials.
- In 2006 Co-founded CLS Pharmaceuticals with two ophthalmologists, and invented & advanced a novel ophthalmic drug candidate, FST-100 into phase II trials, leading to an out-license to Foresight Biotherapeutics, a New York biotech company.
- Former Senior Scientist at Pharmacopeia, Inc. in New Jersey, leading medicinal chemistry development of first-in-class small molecule therapeutics for respiratory and CNS diseases.
- Holds over 50 issued international patents and patent applications.
- Was a reviewer for Journal of Bioorganic and Medicinal Chemistry.
- Co-Founder of Sino-American Pharmaceutical Professionals Association-Greater Philadelphia (SAPA-GP) and served as the first President from 2002 to 2004.
- Obtained his PhD in chemistry from the University of Pennsylvania, MBA from the Stern School of Business of NYU, and Bachelor of chemistry from Peking University in China.
